How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update

As the use of cancer immunotherapy with immune checkpoint inhibitors (ICIs) is expanding rapidly for the treatment of many tumor types, it is crucial that both neurologists and oncologists become familiar with the diagnosis and treatment of neurological immune-related adverse events (n-irAEs). These...

Ausführliche Beschreibung